Logo Image
Opinion|Videos|August 13, 2024

Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment

In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.

Episodes in this series

Video content above is prompted by the following question:

  • Where do you see certain prescriptions fitting into treatment algorithms for patients living with chronic spontaneous urticaria (CSU)?

a. Given the data you’ve seen to date, how would you advise managed

  • Another Bruton tyrosine kinase inhibitor, rilzabrutinib, is also under investigation for patients living with CSU. What stage of development is this molecule in and what has the data demonstrated?
  • How do you see treatment algorithms changing in the future with the introduction of newer classes of therapies?

a. With potential new treatment options on the horizon, how do you think payers should anticipate covering CSU in the next few years?

Related Content